Investigational drug · Phase 2
SUL-238
Also called: t.i.d.
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Parkinson's Disease (PD).
Phase 2Last checked: Nov 20, 2026Latest source record: Aug 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "SUL-238"
First trial start
2026
May 21, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SUL-238", any sponsor or status.
Conditions studied
As listed on its trial records.
- Parkinson's Disease (PD)
Approved drugs for the same conditions: Parkinson's disease · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "SUL-238" as an intervention, largest first.
- A First-In-Human Study of Single and Multiple Ascending Doses of Oral SUL-238 in Healthy SubjectsCompleted
GEN İlaç ve Sağlık Ürünleri A.Ş.Industry
NCT06277492 · 83 participants · Start Feb 19, 2024 · Primary completion Jul 11, 2025
Drug: Single ascending doses SUL-238; Single dose Placebo and 5 more · For: Healthy Subjects
Sites: Kayseri, Turkey (Türkiye)
GEN İlaç ve Sağlık Ürünleri A.Ş.Industry
NCT07322887 · 45 participants (planned) · Start May 21, 2026 · Primary completion May 1, 2027
Drug: SUL-238 (1500 mg t.i.d.) film-coated tablets; SUL-238 (500 mg t.i.d.) film-coated tablets and 1 more · For: Parkinson's Disease (PD)
Sites: Groningen, Netherlands
Newest research
PubMed records naming it or its code names, newest first.
- Comparison of Keverprazan-based versus esomeprazole-based dual therapy for initial treatment of Helicobacter pylori infection: a prospective, multicenter, randomized controlled trial.
Ma Z, Gou X, Ma H, et al. · Ann Med 2026
- Population Pharmacokinetic Model for 6-chromanol SUL-238 Across Rats and Minipigs, a Novel Drug Designed to Protect and Restore Mitochondrial Function.
Swart DH, Westra N, Simon MA, et al. · AAPS J 2026
- Hydralazine-isosorbide dinitrate in chronic heart failure with reduced ejection fraction: the H-HeFT trial.
Køber L, Skak-Hansen KW, Larsen AH, et al. · Eur Heart J 2026
- Optimization of Minocycline-Containing Bismuth Quadruple Therapy for Helicobacter pylori Rescue Treatment: A Randomized Controlled Trial.
Gao Y, Huang Y, Chen J, et al. · J Gastroenterol Hepatol 2026
- Acquired apparent mineralocorticoid excess induced by compound glycyrrhizin tablets: A case report and literature review.
Li Y, Du J, Ma G · Int J Clin Pharmacol Ther 2026
- LeiCNS-PK3.2: A physiologically based pharmacokinetic model framework for predicting intracellular concentrations of acyclovir and ganciclovir active metabolites.
Sun M, Manson ML, Guo T, et al. · Eur J Pharm Sci 2026
Also in development for Parkinson's Disease (PD)
- buntanetapposiphenPhase 33 trials
Annovis Bio Inc. · Early Alzheimers Disease, Alzheimer's Dementia (AD), Parkinson's Disease (PD)
- TJ0113Phase 33 trials
Hangzhou PhecdaMed Co., Ltd. · Sarcopenia, Parkinson's Disease (PD), Parkinson Disease 6, Early-Onset
- TB006Phase 21 trial
TrueBinding, Inc. · Parkinson's Disease (PD)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.